HomeOrthAlign Inc.OrthAlign, Inc. Announces First KneeAlign Cases for Total Knee Arthroplasty in Greece

OrthAlign, Inc. Announces First KneeAlign Cases for Total Knee Arthroplasty in Greece

 

OrthAlign, Inc., a privately held U.S.-based medical device and technology company providing orthopedic surgeons with advanced precision technologies, announced today the first set of KneeAlign® cases completed for total knee arthroplasty (TKA) in Greece. These cases were completed by Athens-based orthopaedic surgeon Spyridon Armpis, MD, MSc and continue to reflect the rapid adoption of OrthAlign’s handheld precision alignment and positioning technologies, by surgeons throughout the world.

Dr. Armpis with OrthAlign Technology
Dr. Armpis with OrthAlign Technology

OrthAlign, Inc., a privately held U.S.-based medical device and technology company providing orthopedic surgeons with advanced precision technologies, announced today the first set of KneeAlign® cases completed for total knee arthroplasty (TKA) in Greece. These cases were completed by Athens-based orthopaedic surgeon Spyridon Armpis, MD, MSc and continue to reflect the rapid adoption of OrthAlign’s handheld precision alignment and positioning technologies, by surgeons throughout the world.

OrthAlign provides highly accurate, computer-assisted, handheld technologies for surgeons to receive real-time, actionable data for precise alignment and positioning of components in total knee, unicondylar knee, and total hip (both posterior and anterior) arthroplasty surgeries. Over 15 peer-reviewed clinical studies have been published to date, validating OrthAlign’s accuracy, simplicity of use, and benefits in recovery for the patient.

“The accuracy and simplicity of KneeAlign surprised me,” said Dr. Armpis. “The technology not only gives me confidence in my cuts, but allows me to elevate my standard of care for patients. I no longer have to invade the intramedullary canal, I don’t have to make multiple cuts, and it makes me, my OR staff, and the recovery process for my patients more efficient. Going forward, KneeAlign will be a key part of my practice and my patient-tailored recovery program, as I am convinced it will give my patients the best possible outcomes.”

In a published TKA clinical study by Denis Nam, M.D. (Rush University Medical Center, Chicago, IL), significant differences favoring the use of KneeAlign vs. conventional Computer Assisted Surgery were found with regard to the accuracy of femoral component alignment, with 94.9% of patients in the KneeAlign cohort having an alignment within 2° of neutral vs. 92.5% in the CAS cohort. There was also a significant difference in overall mean mechanical alignment of the limb, with 92.5% of patients within 3° of neutral mechanical axis in the KneeAlign cohort vs. 86.3% in the CAS cohort.

In another study by Dr. Nam (conducted as a randomized controlled trial, consisting of five different surgeons), it was found that KneeAlign decreases the incidence of outliers for tibial component alignment in both the coronal and sagittal planes, and improves the surgeon’s ability to achieve a specific, intraoperative goal, compared to conventional, tibial extramedullary (EM) alignment guides in TKA. In the KneeAlign cohort, 95.7% of tibial components were within 2° of perpendicular to the tibial mechanical axis and 95% of tibial components were within 2° of a 3° posterior slope (compared to 68.1% and 72.1% in the EM cohort, respectively).

“OrthAlign is delighted to have successfully completed its first KneeAlign cases in Athens,” said James Young Kim, OrthAlign’s Vice President and General Manager of International. “As Greece comprises of 25,000 TKAs annually, it is seeking a cost-effective solution that helps surgeons achieve quicker, more precise results for their patients. Dr. Armpis approached us with this strong desire and was the first surgeon in Greece to experience the power of KneeAlign. As OrthAlign continues to focus on expanding customer reach and portfolio expansion, we welcome the country of Greece to the OrthAlign family and look forward to further introducing it in the Greek orthopaedic market.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

By using this website you agree to accept Medical Device News Magazine Privacy Policy